Tamás Pintér

13.5k total citations · 2 hit papers
51 papers, 5.9k citations indexed

About

Tamás Pintér is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Tamás Pintér has authored 51 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 14 papers in Cancer Research. Recurrent topics in Tamás Pintér's work include Cancer Treatment and Pharmacology (18 papers), Advanced Breast Cancer Therapies (16 papers) and HER2/EGFR in Cancer Research (12 papers). Tamás Pintér is often cited by papers focused on Cancer Treatment and Pharmacology (18 papers), Advanced Breast Cancer Therapies (16 papers) and HER2/EGFR in Cancer Research (12 papers). Tamás Pintér collaborates with scholars based in Hungary, Germany and United States. Tamás Pintér's co-authors include J. Załuski, Eric Van Cutsem, G. Bodoky, Robert Lim, Christopher Stroh, Geert D’Haens, Erika Hitre, Johannes Nippgen, Anatoly Makhson and Jae Kyung Roh and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Tamás Pintér

47 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

2009 2.9k citations Eric Van Cutsem, Claus-Henning Köhne et al. New England Journal of Medicine profile →
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

2014 1.4k citations Richard S. Finn, John Crown et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Tamás Pintér

Since Specialization

Citations

This map shows the geographic impact of Tamás Pintér's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tamás Pintér with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tamás Pintér more than expected).

Fields of papers citing papers by Tamás Pintér

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tamás Pintér. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tamás Pintér. The network helps show where Tamás Pintér may publish in the future.

Co-authorship network of co-authors of Tamás Pintér

This figure shows the co-authorship network connecting the top 25 collaborators of Tamás Pintér. A scholar is included among the top collaborators of Tamás Pintér based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tamás Pintér. Tamás Pintér is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Application of comprehensive molecular genetic profiling in precision cancer medicine, Hungarian experiences 2024 ·Acta Oncologica ·Erika Tóth, (unknown), (unknown), Tamás Pintér, Henriett Butz, Zsolt Horváth, (unknown), Vince Kornél Grolmusz, Judit Székely, (unknown), József Lövey, (unknown), (unknown), Péter Nagy, Csaba Polgár, Attila Patócs	0
2	Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study 2024 ·The Breast ·Gilles Freyer, Noelia Martínez-Jáñez, Bożena Kukiełka-Budny, Małgorzata Ułańska, Hugues Bourgeois, Montserrat Muñoz-Mateu, Serafín Morales, (unknown), Laura Cortesi, Tamás Pintér, Markéta Palácová, (unknown), Edgar Petru, Johannes Ettl, (unknown), G. Villanova, (unknown), (unknown), Ana Rodrigues, Marina Elena Cazzaniga	1
3	Recurrent pneumothoraces caused by a high-grade lung carcinoma with trophoblastic differentiation: a case report 2024 ·Frontiers in Oncology ·(unknown), (unknown), (unknown), Tamás Pintér, László Agócs, Balázs Döme, F Rényi-Vámos, (unknown)	0
4	Daganatos nőbetegek termékenységének megőrzése. 2023 ·Orvosi Hetilap ·(unknown), Borbála Székely, (unknown), András Masszi, Tamás Pintér, (unknown), István Kenessey, Gábor Rubovszky, Zoltán Novàk	1
5	Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) 2020 ·Breast Cancer Research and Treatment ·Richard S. Finn, Katalin Boér, Igor Bondarenko, Ravindranath Patel, Tamás Pintér, Marcus Schmidt, Yaroslav Shparyk, Anu Thummala, Олександр Войтко, Eustratios Bananis, Lynn McRoy, Keith D. Wilner, Xin Huang, Sindy Kim, Dennis J. Slamon, Johannes Ettl	111
6	Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer 2017 ·Pathology & Oncology Research ·Gábor Rubovszky, Barna Budai, (unknown), Zsolt Horváth, É Juhos, (unknown), Tünde Nagy, Eszter Szabó, Tamás Pintér, Erika Tóth, Péter Nagy, István Láng, Erika Hitre	5
7	Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18 2016 ·Breast Cancer Research ·Richard S. Finn, John Crown, Johannes Ettl, Marcus Schmidt, Igor Bondarenko, István Láng, Tamás Pintér, Katalin Boér, Ravindranath Patel, Sophia Randolph, Sindy T. Kim, Xin Huang, Patrick Schnell, Sashi Nadanaciva, Cynthia Huang Bartlett, Dennis J. Slamon	136
8	Clinical efficacy and safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment in patients (pts) with ER+ and HER2- advanced breast cancer (ABC) who have not received any systemic treatment (ST): A subgroup analysis of PALOMA-1/TRIO-18. 2015 ·Journal of Clinical Oncology ·Richard S. Finn, John Crown, Johannes Ettl, Tamás Pintér, Anu Thummala, Yaroslav Shparyk, Ravi Patel, Sophia Randolph, Sindy Kim, Xin Huang, Yuqiu Jiang, Cynthia Huang Bartlett, Dennis J. Slamon	1
9	The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study breakdown → 2014 ·The Lancet Oncology ·Richard S. Finn, John Crown, István Láng, Katalin Boér, Igor Bondarenko, (unknown), Johannes Ettl, Ravindranath Patel, Tamás Pintér, Marcus Schmidt, Yaroslav Shparyk, Anu Thummala, (unknown), Camilla Fowst, Xin Huang, Sindy T. Kim, Sophia Randolph, Dennis J. Slamon	1412
10	Health-Related Quality of Life With Adjuvant Docetaxel- and Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Node-Negative, HER2-Positive Early Breast Cancer: Results from the BCIRG 006 Study 2013 ·The Oncologist ·Heather‐Jane Au, W. Eiermann, Nicholas J. Robert, Tadeusz Pieńkowski, John Crown, Miguel Martín, Marek Pawlicki, Arlene Chan, John R. Mackey, John A. Glaspy, Tamás Pintér, Mei-Ching Liu, Tommy� Fornander, Sandeep Sehdev, Jean-Marc Ferrero, Valerie Bée, Maria Santana, Dave P. Miller, Deepa Lalla, Dennis J. Slamon	19
11	Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II) 2012 ·Journal of Clinical Oncology ·Paulo M. Hoff, Andreas Hochhaus, Bernhard C. Pestalozzi, Niall C. Tebbutt, Jin Li, Tae Won Kim, Krassimir Koynov, G. Kurteva, Tamás Pintér, Ying Cheng, Brigitte Van Eyll, Laura A. Pike, Anitra Fielding, Jane Robertson, Mark Saunders	112
12	New European Initiatives in Colorectal Cancer Screening: Budapest Declaration 2012 ·Digestive Diseases ·Tibor Wittmann, Reinhold W. Stockbrügger, László Herszényi, Daisy Jonkers, Béla Molnár, Jean-Christophe Saurin, Jarosław Reguła, Alberto Malesci, Luigi Laghi, Tamás Pintér, Béla Teleky, Petr Dítě, Zsolt Tulassay	9
13	Az emlőrák belgyógyászati onkológiai (gyógyszeres) kezelése 2010 ·PubMed ·István Láng, Zsuzsanna Kahán, Tamás Pintér, Magdolna Dank, Katalin Boér, Gábor Pajkos, Zsolt Faluhelyi, Béla Pikó, S. Gail Eckhardt, Zsolt Horváth	4
14	Abstract S4-3: Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer 2010 ·Cancer Research ·Miguel Martín, John R. Mackey, Tadeusz Pieńkowski, Janusz Rolski, J P Guastalla, Amer Sami, John A. Glaspy, É Juhos, Andrew Wardley, Tommy� Fornander, John D. Hainsworth, Robert E. Coleman, Manuel Modiano, J. Vinholes, Tamás Pintér, Barrett H. Childs, Martin Roessner, Vickie S. Wilson, Matthieu Rupin, Charles L. Vogel	2
15	Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer breakdown → 2009 ·New England Journal of Medicine ·Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, J. Załuski, (unknown), Anatoly Makhson, Geert D’Haens, Tamás Pintér, Robert Lim, G. Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier	2902
16	TRIO-012: A Multicenter, Multinational, Randomized, Double-Blind Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally Recurrent or Metastatic Breast Cancer 2009 ·Clinical Breast Cancer ·John R. Mackey, Karen A. Gelmon, Miguel Martín, Nicole McCarthy, Tamás Pintér, (unknown), Hagop Youssoufian	25
17	Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases 2006 ·British Journal of Cancer ·Baldassarre Stea, Edward Shaw, Tamás Pintér, (unknown), Michael Craig, (unknown), R. Steffen, John H. Suh	6
18	Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy 2005 ·European Journal of Cancer ·Svein Inge Helle, William Mietlowski, Jean Paul Guastalla, (unknown), Emilio Bajetta, H. Sommer, (unknown), Tamás Pintér, (unknown), Lars Ottestad, C. Boni, C. Bryce, J.G.M. Klijn, Per Eystein Lønning	7
19	Topoisomerase II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated with single-agent doxorubicin or single-agent docetaxel 2004 ·Cancer Research ·Christine Desmedt, Virginie Durbecq, Marianne Paesmans, Christos Sotiriou, Jean-Yves Leroy, Ghizlane Rouas, Stephen Chan, Kay Friedrichs, Tamás Pintér, Sebastian Belle, Elizabeth Murray, (unknown), Steven R. Olsen, Angelo Di Leo, Fátima Cardoso, Martine Piccart, Denis Larsimont	40
20	HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel 2004 ·Breast Cancer Research and Treatment ·Angelo Di Leo, Stephen Chan, Marianne Paesmans, Kay Friedrichs, Tamás Pintér, V. Cocquyt, Elizabeth Murray, I. Bodrogi, Euan Walpole, Bernard Lespérance, S Korec, John Crown, Peter Simmonds, Gϋnter von Minckwitz, Jean-Yves Leroy, Virginie Durbecq, Jorma Isola, Matti Aapro, Martine Piccart, Denis Larsimont	121

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact